(DOCS) Doximity - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US26622P1075
Stock: Platform, Network, Collaboration, Telehealth, Recruitment
Total Rating 32
Risk 93
Buy Signal -0.18
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 109% |
| Relative Tail Risk | -27.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.95 |
| Alpha | -69.44 |
| Character TTM | |
|---|---|
| Beta | 1.129 |
| Beta Downside | 1.413 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.65% |
| CAGR/Max DD | -0.07 |
Description: DOCS Doximity January 03, 2026
Doximity, Inc. (NYSE: DOCS) runs a U.S.-focused digital network for physicians, nurse practitioners, physician assistants, medical students, pharma firms, and health systems, offering tools for peer collaboration, news aggregation, career management, on-call scheduling, documentation, and virtual patient visits.
Founded in 2010 (originally 3MD Communications) and headquartered in San Francisco, the company sits in the Health Care Technology sub-industry and trades as common stock.
Key recent metrics: FY 2023 revenue topped $460 million, up ~30 % YoY, driven by a 20 % increase in advertising spend and a 15 % rise in subscription-based services; the platform now reaches roughly 84 % of U.S. physicians, giving it a highly defensible network effect.
Sector drivers include accelerating adoption of telehealth post-COVID-19, ongoing physician shortages that push clinicians toward efficiency-enhancing software, and rising health-system budgets for digital infrastructure, all of which support Doximity’s growth outlook.
For a deeper dive into Doximity’s valuation and risk profile, check the ValueRay analysis page.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 253.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.25 > 0.02 and ΔFCF/TA 5.58 > 1.0 |
| NWC/Revenue: 153.2% < 20% (prev 159.7%; Δ -6.50% < -1%) |
| CFO/TA 0.25 > 3% & CFO 319.7m > Net Income 253.0m |
| Net Debt (-158.0m) to EBITDA (279.1m): -0.57 < 3 |
| Current Ratio: 7.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (200.7m) vs 12m ago 0.17% < -2% |
| Gross Margin: 90.20% > 18% (prev 0.90%; Δ 8930 % > 0.5%) |
| Asset Turnover: 52.31% > 50% (prev 46.21%; Δ 6.10% > 0%) |
| Interest Coverage Ratio: -13.54 > 6 (EBITDA TTM 279.1m / Interest Expense TTM -19.6m) |
Altman Z'' 7.92
| A: 0.76 (Total Current Assets 1.09b - Total Current Liabilities 140.3m) / Total Assets 1.26b |
| B: 0.13 (Retained Earnings 157.7m / Total Assets 1.26b) |
| C: 0.22 (EBIT TTM 265.7m / Avg Total Assets 1.19b) |
| D: 0.99 (Book Value of Equity 159.4m / Total Liabilities 161.6m) |
| Altman-Z'' Score: 7.92 = AAA |
Beneish M -3.11
| DSRI: 0.86 (Receivables 129.3m/124.8m, Revenue 621.3m/516.8m) |
| GMI: 1.00 (GM 90.20% / 89.94%) |
| AQI: 0.91 (AQ_t 0.11 / AQ_t-1 0.12) |
| SGI: 1.20 (Revenue 621.3m / 516.8m) |
| TATA: -0.05 (NI 253.0m - CFO 319.7m) / TA 1.26b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of DOCS shares?
As of February 07, 2026, the stock is trading at USD 27.73 with a total of 22,179,473 shares traded.
Over the past week, the price has changed by -25.99%, over one month by -39.31%, over three months by -55.69% and over the past year by -52.40%.
Over the past week, the price has changed by -25.99%, over one month by -39.31%, over three months by -55.69% and over the past year by -52.40%.
Is DOCS a buy, sell or hold?
Doximity has received a consensus analysts rating of 3.68.
Therefor, it is recommend to hold DOCS.
- StrongBuy: 5
- Buy: 3
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DOCS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 63 | 127.2% |
| Analysts Target Price | 63 | 127.2% |
| ValueRay Target Price | 26.4 | -4.7% |
DOCS Fundamental Data Overview February 03, 2026
P/E Trailing = 30.9669
P/E Forward = 22.4719
P/S = 11.3539
P/B = 6.6387
P/EG = 0.9765
Revenue TTM = 621.3m USD
EBIT TTM = 265.7m USD
EBITDA TTM = 279.1m USD
Long Term Debt = 11.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.12m USD (from shortTermDebt, last quarter)
Debt = 11.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -158.0m USD (from netDebt column, last quarter)
Enterprise Value = 6.19b USD (7.05b + Debt 11.3m - CCE 878.4m)
Interest Coverage Ratio = -13.54 (Ebit TTM 265.7m / Interest Expense TTM -19.6m)
EV/FCF = 19.68x (Enterprise Value 6.19b / FCF TTM 314.5m)
FCF Yield = 5.08% (FCF TTM 314.5m / Enterprise Value 6.19b)
FCF Margin = 50.61% (FCF TTM 314.5m / Revenue TTM 621.3m)
Net Margin = 40.72% (Net Income TTM 253.0m / Revenue TTM 621.3m)
Gross Margin = 90.20% ((Revenue TTM 621.3m - Cost of Revenue TTM 60.9m) / Revenue TTM)
Gross Margin QoQ = 90.25% (prev 89.18%)
Tobins Q-Ratio = 4.92 (Enterprise Value 6.19b / Total Assets 1.26b)
Interest Expense / Debt = 34.39% (Interest Expense 3.88m / Debt 11.3m)
Taxrate = 14.92% (10.9m / 72.9m)
NOPAT = 226.1m (EBIT 265.7m * (1 - 14.92%))
Current Ratio = 7.79 (Total Current Assets 1.09b / Total Current Liabilities 140.3m)
Debt / Equity = 0.01 (Debt 11.3m / totalStockholderEquity, last quarter 1.10b)
Debt / EBITDA = -0.57 (Net Debt -158.0m / EBITDA 279.1m)
Debt / FCF = -0.50 (Net Debt -158.0m / FCF TTM 314.5m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.30% (Net Income 253.0m / Total Assets 1.26b)
RoE = 23.90% (Net Income TTM 253.0m / Total Stockholder Equity 1.06b)
RoCE = 24.83% (EBIT 265.7m / Capital Employed (Equity 1.06b + L.T.Debt 11.3m))
RoIC = 21.35% (NOPAT 226.1m / Invested Capital 1.06b)
WACC = 10.11% (E(7.05b)/V(7.07b) * Re(10.08%) + D(11.3m)/V(7.07b) * Rd(34.39%) * (1-Tc(0.15)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.07%
[DCF Debug] Terminal Value 74.72% ; FCFF base≈275.6m ; Y1≈340.0m ; Y5≈579.1m
Fair Price DCF = 50.89 (EV 6.83b - Net Debt -158.0m = Equity 6.99b / Shares 137.4m; r=10.11% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 40.18 | EPS CAGR: -45.79% | SUE: -4.0 | # QB: 0
Revenue Correlation: 92.82 | Revenue CAGR: 15.59% | SUE: 2.30 | # QB: 2
EPS next Year (2027-03-31): EPS=1.73 | Chg30d=+0.003 | Revisions Net=+1 | Growth EPS=+10.0% | Growth Revenue=+11.2%
P/E Forward = 22.4719
P/S = 11.3539
P/B = 6.6387
P/EG = 0.9765
Revenue TTM = 621.3m USD
EBIT TTM = 265.7m USD
EBITDA TTM = 279.1m USD
Long Term Debt = 11.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.12m USD (from shortTermDebt, last quarter)
Debt = 11.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -158.0m USD (from netDebt column, last quarter)
Enterprise Value = 6.19b USD (7.05b + Debt 11.3m - CCE 878.4m)
Interest Coverage Ratio = -13.54 (Ebit TTM 265.7m / Interest Expense TTM -19.6m)
EV/FCF = 19.68x (Enterprise Value 6.19b / FCF TTM 314.5m)
FCF Yield = 5.08% (FCF TTM 314.5m / Enterprise Value 6.19b)
FCF Margin = 50.61% (FCF TTM 314.5m / Revenue TTM 621.3m)
Net Margin = 40.72% (Net Income TTM 253.0m / Revenue TTM 621.3m)
Gross Margin = 90.20% ((Revenue TTM 621.3m - Cost of Revenue TTM 60.9m) / Revenue TTM)
Gross Margin QoQ = 90.25% (prev 89.18%)
Tobins Q-Ratio = 4.92 (Enterprise Value 6.19b / Total Assets 1.26b)
Interest Expense / Debt = 34.39% (Interest Expense 3.88m / Debt 11.3m)
Taxrate = 14.92% (10.9m / 72.9m)
NOPAT = 226.1m (EBIT 265.7m * (1 - 14.92%))
Current Ratio = 7.79 (Total Current Assets 1.09b / Total Current Liabilities 140.3m)
Debt / Equity = 0.01 (Debt 11.3m / totalStockholderEquity, last quarter 1.10b)
Debt / EBITDA = -0.57 (Net Debt -158.0m / EBITDA 279.1m)
Debt / FCF = -0.50 (Net Debt -158.0m / FCF TTM 314.5m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.30% (Net Income 253.0m / Total Assets 1.26b)
RoE = 23.90% (Net Income TTM 253.0m / Total Stockholder Equity 1.06b)
RoCE = 24.83% (EBIT 265.7m / Capital Employed (Equity 1.06b + L.T.Debt 11.3m))
RoIC = 21.35% (NOPAT 226.1m / Invested Capital 1.06b)
WACC = 10.11% (E(7.05b)/V(7.07b) * Re(10.08%) + D(11.3m)/V(7.07b) * Rd(34.39%) * (1-Tc(0.15)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.07%
[DCF Debug] Terminal Value 74.72% ; FCFF base≈275.6m ; Y1≈340.0m ; Y5≈579.1m
Fair Price DCF = 50.89 (EV 6.83b - Net Debt -158.0m = Equity 6.99b / Shares 137.4m; r=10.11% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 40.18 | EPS CAGR: -45.79% | SUE: -4.0 | # QB: 0
Revenue Correlation: 92.82 | Revenue CAGR: 15.59% | SUE: 2.30 | # QB: 2
EPS next Year (2027-03-31): EPS=1.73 | Chg30d=+0.003 | Revisions Net=+1 | Growth EPS=+10.0% | Growth Revenue=+11.2%